Literature DB >> 408005

Regression of human lung tumor xenografts induced by water-soluble analogs of hexamethylmelamine.

T A Connors, A J Cumber, W C Ross, S A Clarke, B C Mitchley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 408005

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


× No keyword cloud information.
  8 in total

1.  Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.

Authors:  E Boven; M M Nauta; H M Schlüper; C A Erkelens; H M Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  Preclinical toxicology, pharmacokinetics and formulation of N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine (trimelamol), a water-soluble cytotoxic s-triazine which does not require metabolic activation.

Authors:  C J Rutty; I R Judson; G Abel; P M Goddard; D R Newell; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 3.  New cancer chemotherapy drugs in Europe.

Authors:  G Mathé; L M van Putten
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

4.  The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse.

Authors:  C J Rutty; D R Newell; J R Muindi; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 5.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 6.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

7.  Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

Authors:  K J Miller; R M McGovern; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

8.  Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies.

Authors:  J R Muindi; D R Newell; I E Smith; K R Harrap
Journal:  Br J Cancer       Date:  1983-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.